Coronavirus vaccine: “If launching a vaccine prior to completion of Phase 3 trials is acceptable to Russia, well so be it,” Mazumdar-Shaw said.
Biotechnology industry veteran Kiran Mazumdar-Shaw has questioned Russian claims of developing the world’s first safe coronavirus vaccine, citing absence of data on clinical trials and “more advanced” programmes elsewhere.
The world has not seen any data on Phase 1 or 2 clinical trials conducted by Moscow-based Gamaleya Research Institute, the Executive Chairperson of Bengaluru-headquartered Biocon Ltd said.
“If launching a vaccine prior to completion of Phase 3 trials is acceptable to Russia, well so be it,” Mazumdar-Shaw told PTI.
“But it doesn’t make them the world’s first vaccine as several other vaccine programmes are even more advanced,” she added.
Russia announced on Tuesday it had become the first country to grant regulatory approval to a COVID-19 vaccine.
The first dose of the vaccine-Sputnik-V, developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry, was administered to Russian President Vladimir Putin’s daughter.
Amid the race to develop a Coronavirus vaccine, Russian President Vladimir Putin launched a coronavirus vaccine, touted as the world’s first such vaccine too. The registration of the vaccine lays ground for for mass inoculation even as the final stages of clinical trials to test safety and efficacy continue.
The president also asked Health Minister Mikhail Murashko to keep him informed about the vaccine, while at the same time noting that he knows “it works quite effectively” and “forms a stable immunity”.
Russia’s first coronavirus vaccine is developed jointly by Gamaleya Research Institute and the Russian Defence Ministry.